| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Oncogene Proteins, Fusion | 16 | 2025 | 64 | 3.900 |
Why?
|
| Leukemia, Myeloid, Acute | 10 | 2025 | 191 | 2.460 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 11 | 2025 | 82 | 1.620 |
Why?
|
| Core Binding Factor beta Subunit | 8 | 2025 | 22 | 1.380 |
Why?
|
| Chromosome Inversion | 3 | 2024 | 18 | 1.080 |
Why?
|
| Blood Platelet Disorders | 2 | 2025 | 4 | 1.040 |
Why?
|
| Myosin Heavy Chains | 3 | 2025 | 48 | 0.970 |
Why?
|
| Chromosomes, Human, Pair 16 | 2 | 2024 | 23 | 0.930 |
Why?
|
| Leukemia, Myeloid | 4 | 2006 | 35 | 0.920 |
Why?
|
| Oncogenes | 4 | 2020 | 70 | 0.890 |
Why?
|
| Cell Proliferation | 7 | 2024 | 1036 | 0.880 |
Why?
|
| Neuropilin-1 | 1 | 2024 | 13 | 0.870 |
Why?
|
| Hematologic Neoplasms | 1 | 2023 | 45 | 0.780 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2024 | 234 | 0.770 |
Why?
|
| Signal Transduction | 5 | 2025 | 3149 | 0.750 |
Why?
|
| Receptors, Thrombopoietin | 2 | 2012 | 4 | 0.710 |
Why?
|
| Mice | 26 | 2025 | 11114 | 0.690 |
Why?
|
| Hematopoiesis | 7 | 2025 | 127 | 0.690 |
Why?
|
| Preleukemia | 2 | 2014 | 3 | 0.660 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2018 | 113 | 0.650 |
Why?
|
| Transcription Factors | 10 | 2018 | 1554 | 0.640 |
Why?
|
| Lipoylation | 1 | 2020 | 5 | 0.640 |
Why?
|
| DNA-Binding Proteins | 9 | 2018 | 1225 | 0.620 |
Why?
|
| Apoptosis | 7 | 2024 | 1100 | 0.590 |
Why?
|
| Leukemia, Myelomonocytic, Acute | 3 | 2008 | 4 | 0.560 |
Why?
|
| Animals | 29 | 2025 | 21333 | 0.550 |
Why?
|
| Hematopoietic Stem Cells | 7 | 2025 | 299 | 0.540 |
Why?
|
| RNA-Binding Proteins | 3 | 2024 | 447 | 0.460 |
Why?
|
| Chromatin | 3 | 2023 | 641 | 0.450 |
Why?
|
| Oncogene Proteins | 1 | 2014 | 33 | 0.420 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2012 | 215 | 0.410 |
Why?
|
| Monomeric GTP-Binding Proteins | 1 | 2014 | 43 | 0.400 |
Why?
|
| Cell Line, Tumor | 7 | 2024 | 1566 | 0.390 |
Why?
|
| Core Binding Factor alpha Subunits | 2 | 2016 | 20 | 0.390 |
Why?
|
| Cell Differentiation | 5 | 2025 | 1386 | 0.390 |
Why?
|
| Mice, Transgenic | 7 | 2025 | 1290 | 0.370 |
Why?
|
| Myeloid Progenitor Cells | 3 | 2008 | 12 | 0.370 |
Why?
|
| Thrombopoietin | 1 | 2012 | 11 | 0.370 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2012 | 178 | 0.350 |
Why?
|
| Germ-Line Mutation | 3 | 2023 | 47 | 0.340 |
Why?
|
| Core Binding Factor Alpha 1 Subunit | 2 | 2009 | 142 | 0.320 |
Why?
|
| Gene Expression Regulation, Leukemic | 4 | 2025 | 51 | 0.320 |
Why?
|
| Proto-Oncogene Proteins | 4 | 2021 | 343 | 0.310 |
Why?
|
| Transcription, Genetic | 3 | 2011 | 907 | 0.300 |
Why?
|
| CCAAT-Enhancer-Binding Protein-alpha | 1 | 2008 | 14 | 0.280 |
Why?
|
| Lymphoid Progenitor Cells | 1 | 2007 | 6 | 0.270 |
Why?
|
| DNA | 5 | 2023 | 858 | 0.270 |
Why?
|
| Breast Neoplasms | 7 | 2022 | 1222 | 0.270 |
Why?
|
| Molecular Sequence Data | 12 | 2012 | 1979 | 0.260 |
Why?
|
| Inflammation | 2 | 2025 | 1187 | 0.260 |
Why?
|
| Benzimidazoles | 2 | 2018 | 56 | 0.240 |
Why?
|
| Promoter Regions, Genetic | 4 | 2021 | 687 | 0.240 |
Why?
|
| Mice, Inbred C57BL | 6 | 2018 | 3481 | 0.240 |
Why?
|
| Humans | 28 | 2025 | 65141 | 0.230 |
Why?
|
| Transcriptional Regulator ERG | 1 | 2024 | 9 | 0.220 |
Why?
|
| Pancytopenia | 1 | 2024 | 7 | 0.210 |
Why?
|
| Acute Disease | 4 | 2006 | 663 | 0.200 |
Why?
|
| Disease Susceptibility | 1 | 2023 | 169 | 0.200 |
Why?
|
| Nucleic Acids | 1 | 2024 | 66 | 0.190 |
Why?
|
| Base Sequence | 9 | 2011 | 1329 | 0.190 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2018 | 415 | 0.190 |
Why?
|
| Trans-Activators | 2 | 2021 | 321 | 0.180 |
Why?
|
| Granulocytes | 2 | 1999 | 73 | 0.180 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2022 | 63 | 0.180 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2022 | 71 | 0.180 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2023 | 350 | 0.170 |
Why?
|
| Bone Marrow Transplantation | 2 | 2012 | 140 | 0.170 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2016 | 583 | 0.170 |
Why?
|
| Neoplasm Proteins | 4 | 1995 | 285 | 0.170 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2012 | 542 | 0.160 |
Why?
|
| Genes, ras | 1 | 2020 | 28 | 0.160 |
Why?
|
| Antineoplastic Agents | 2 | 2016 | 644 | 0.160 |
Why?
|
| Neutrophils | 1 | 2023 | 390 | 0.160 |
Why?
|
| Tumor Cells, Cultured | 3 | 2021 | 426 | 0.160 |
Why?
|
| Neoplastic Stem Cells | 2 | 2014 | 195 | 0.150 |
Why?
|
| Bone Marrow | 2 | 2012 | 176 | 0.150 |
Why?
|
| Mutation, Missense | 2 | 2025 | 190 | 0.150 |
Why?
|
| Nuclear Proteins | 3 | 2018 | 790 | 0.150 |
Why?
|
| Protein Binding | 3 | 2018 | 1639 | 0.150 |
Why?
|
| Azepines | 1 | 2018 | 22 | 0.140 |
Why?
|
| Polycomb Repressive Complex 1 | 1 | 2018 | 31 | 0.140 |
Why?
|
| RUNX1 Translocation Partner 1 Protein | 2 | 2021 | 11 | 0.140 |
Why?
|
| Triazoles | 1 | 2018 | 63 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-myb | 1 | 2017 | 12 | 0.130 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2017 | 49 | 0.130 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2017 | 119 | 0.120 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2018 | 182 | 0.120 |
Why?
|
| DNA Helicases | 1 | 2018 | 198 | 0.120 |
Why?
|
| Sequence Analysis, DNA | 1 | 2018 | 414 | 0.120 |
Why?
|
| Immunoenzyme Techniques | 2 | 2016 | 108 | 0.120 |
Why?
|
| Cell Survival | 2 | 2017 | 587 | 0.120 |
Why?
|
| Thrombospondins | 1 | 2016 | 6 | 0.120 |
Why?
|
| Cell Cycle | 2 | 2022 | 398 | 0.120 |
Why?
|
| Connexin 43 | 1 | 2016 | 14 | 0.120 |
Why?
|
| Gene Expression Profiling | 2 | 2011 | 794 | 0.120 |
Why?
|
| Mice, Mutant Strains | 3 | 2006 | 301 | 0.120 |
Why?
|
| Computational Biology | 1 | 2018 | 367 | 0.120 |
Why?
|
| Cells, Cultured | 2 | 2011 | 2188 | 0.110 |
Why?
|
| RNA, Messenger | 2 | 2012 | 1575 | 0.110 |
Why?
|
| Forkhead Transcription Factors | 1 | 2016 | 132 | 0.110 |
Why?
|
| Blotting, Western | 2 | 2016 | 610 | 0.110 |
Why?
|
| Amino Acid Sequence | 4 | 2012 | 1589 | 0.110 |
Why?
|
| Hemorrhage | 1 | 1996 | 285 | 0.110 |
Why?
|
| Leukemia, Experimental | 1 | 2014 | 19 | 0.110 |
Why?
|
| Bcl-2-Like Protein 11 | 1 | 2014 | 20 | 0.110 |
Why?
|
| Software | 1 | 2018 | 400 | 0.110 |
Why?
|
| Mice, 129 Strain | 1 | 2014 | 41 | 0.110 |
Why?
|
| Retroviridae | 2 | 2004 | 75 | 0.100 |
Why?
|
| Gene Knock-In Techniques | 1 | 2014 | 48 | 0.100 |
Why?
|
| Ovarian Neoplasms | 2 | 1994 | 166 | 0.100 |
Why?
|
| Translocation, Genetic | 2 | 2012 | 74 | 0.100 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2014 | 152 | 0.100 |
Why?
|
| Adenocarcinoma | 1 | 2016 | 366 | 0.090 |
Why?
|
| MAP Kinase Signaling System | 1 | 2014 | 235 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 21 | 1 | 2012 | 30 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2012 | 33 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 17 | 4 | 1996 | 24 | 0.090 |
Why?
|
| Heterozygote | 2 | 2006 | 173 | 0.090 |
Why?
|
| Sequence Homology, Nucleic Acid | 2 | 2011 | 111 | 0.090 |
Why?
|
| DNA Primers | 4 | 2004 | 301 | 0.090 |
Why?
|
| Cell Lineage | 2 | 2007 | 282 | 0.090 |
Why?
|
| Mutagenesis, Insertional | 2 | 2018 | 94 | 0.090 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2012 | 211 | 0.090 |
Why?
|
| STAT5 Transcription Factor | 1 | 2011 | 14 | 0.080 |
Why?
|
| Polymorphism, Genetic | 5 | 1996 | 198 | 0.080 |
Why?
|
| Cytokines | 3 | 2025 | 952 | 0.080 |
Why?
|
| Janus Kinase 2 | 1 | 2011 | 21 | 0.080 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2011 | 61 | 0.080 |
Why?
|
| Disease Models, Animal | 1 | 2018 | 2293 | 0.080 |
Why?
|
| Luciferases | 1 | 2011 | 107 | 0.080 |
Why?
|
| Immunoblotting | 1 | 2011 | 202 | 0.080 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2011 | 80 | 0.080 |
Why?
|
| Survival Rate | 1 | 2012 | 844 | 0.080 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2011 | 297 | 0.080 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2006 | 730 | 0.080 |
Why?
|
| BRCA1 Protein | 5 | 1996 | 68 | 0.070 |
Why?
|
| Flow Cytometry | 1 | 2011 | 662 | 0.070 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 3 | 1994 | 85 | 0.070 |
Why?
|
| Transfection | 1 | 2011 | 701 | 0.070 |
Why?
|
| Insect Proteins | 2 | 2000 | 82 | 0.070 |
Why?
|
| Membrane Proteins | 1 | 2014 | 918 | 0.070 |
Why?
|
| VDJ Recombinases | 1 | 2007 | 10 | 0.070 |
Why?
|
| Down-Regulation | 1 | 2009 | 324 | 0.070 |
Why?
|
| Mutant Proteins | 1 | 2008 | 105 | 0.070 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2009 | 205 | 0.070 |
Why?
|
| Protein Isoforms | 1 | 2008 | 202 | 0.070 |
Why?
|
| Survival Analysis | 1 | 2009 | 576 | 0.070 |
Why?
|
| Biomarkers, Tumor | 1 | 2011 | 524 | 0.060 |
Why?
|
| Female | 10 | 2022 | 34030 | 0.060 |
Why?
|
| Transcription Factor AP-2 | 2 | 2004 | 11 | 0.060 |
Why?
|
| Muscle, Smooth | 1 | 2006 | 135 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 3 | 2004 | 513 | 0.060 |
Why?
|
| Megakaryocytes | 1 | 2006 | 19 | 0.060 |
Why?
|
| Bone Marrow Cells | 1 | 2006 | 237 | 0.060 |
Why?
|
| Homeodomain Proteins | 1 | 2007 | 277 | 0.060 |
Why?
|
| Neoplasms | 1 | 2016 | 1367 | 0.060 |
Why?
|
| Blood Coagulation Disorders, Inherited | 1 | 2025 | 1 | 0.060 |
Why?
|
| Blood Platelets | 1 | 2006 | 108 | 0.050 |
Why?
|
| G1 Phase | 1 | 2004 | 58 | 0.050 |
Why?
|
| Genotype | 1 | 2006 | 673 | 0.050 |
Why?
|
| Sensitivity and Specificity | 1 | 2007 | 1163 | 0.050 |
Why?
|
| S Phase | 1 | 2004 | 79 | 0.050 |
Why?
|
| Artificial Gene Fusion | 1 | 2004 | 6 | 0.050 |
Why?
|
| Blotting, Southern | 1 | 2004 | 56 | 0.050 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2025 | 132 | 0.050 |
Why?
|
| NIH 3T3 Cells | 1 | 2004 | 99 | 0.050 |
Why?
|
| Mutation | 2 | 2016 | 2661 | 0.050 |
Why?
|
| Guanosine Monophosphate | 1 | 2023 | 2 | 0.050 |
Why?
|
| Models, Biological | 1 | 2009 | 1192 | 0.050 |
Why?
|
| Thionucleotides | 1 | 2023 | 39 | 0.050 |
Why?
|
| STAT1 Transcription Factor | 1 | 2023 | 35 | 0.050 |
Why?
|
| Receptor-Interacting Protein Serine-Threonine Kinases | 1 | 2024 | 84 | 0.050 |
Why?
|
| Necrosis | 1 | 2024 | 148 | 0.050 |
Why?
|
| Drosophila Proteins | 2 | 2000 | 758 | 0.050 |
Why?
|
| B-Lymphocytes | 1 | 2006 | 563 | 0.050 |
Why?
|
| Radiology, Interventional | 1 | 2022 | 31 | 0.050 |
Why?
|
| Cell Death | 1 | 2024 | 289 | 0.050 |
Why?
|
| Monte Carlo Method | 1 | 2022 | 98 | 0.050 |
Why?
|
| Antisense Elements (Genetics) | 1 | 2021 | 7 | 0.040 |
Why?
|
| Cosmids | 4 | 1995 | 8 | 0.040 |
Why?
|
| Gene Fusion | 1 | 2021 | 7 | 0.040 |
Why?
|
| Cell Division | 1 | 2022 | 449 | 0.040 |
Why?
|
| Chromosome Mapping | 7 | 1996 | 295 | 0.040 |
Why?
|
| Monocytes | 1 | 2023 | 361 | 0.040 |
Why?
|
| Huntington Disease | 2 | 1993 | 159 | 0.040 |
Why?
|
| DNA Transposable Elements | 3 | 2018 | 159 | 0.040 |
Why?
|
| Erythroid Precursor Cells | 2 | 1999 | 25 | 0.040 |
Why?
|
| Genes, Lethal | 2 | 1997 | 57 | 0.040 |
Why?
|
| Leukemia | 2 | 2016 | 62 | 0.040 |
Why?
|
| Ethylnitrosourea | 1 | 1999 | 11 | 0.040 |
Why?
|
| Mutagens | 1 | 1999 | 17 | 0.040 |
Why?
|
| Mice, Inbred Strains | 1 | 1999 | 185 | 0.040 |
Why?
|
| Mesoderm | 1 | 1999 | 89 | 0.040 |
Why?
|
| Neovascularization, Physiologic | 1 | 1999 | 113 | 0.030 |
Why?
|
| Web Browser | 1 | 2018 | 7 | 0.030 |
Why?
|
| Transposases | 1 | 2018 | 18 | 0.030 |
Why?
|
| Transcription Initiation Site | 1 | 2018 | 47 | 0.030 |
Why?
|
| Phosphoproteins | 1 | 1999 | 224 | 0.030 |
Why?
|
| T-Cell Acute Lymphocytic Leukemia Protein 1 | 1 | 2017 | 22 | 0.030 |
Why?
|
| Cell Line, Transformed | 1 | 2017 | 97 | 0.030 |
Why?
|
| Lung | 1 | 2022 | 964 | 0.030 |
Why?
|
| Cloning, Molecular | 5 | 1996 | 384 | 0.030 |
Why?
|
| Medulla Oblongata | 1 | 1996 | 7 | 0.030 |
Why?
|
| Facial Nerve | 1 | 1996 | 8 | 0.030 |
Why?
|
| Male | 2 | 2011 | 31055 | 0.030 |
Why?
|
| Receptors, Notch | 1 | 2017 | 110 | 0.030 |
Why?
|
| Crosses, Genetic | 1 | 1996 | 116 | 0.030 |
Why?
|
| Pericardium | 1 | 1996 | 35 | 0.030 |
Why?
|
| Myelodysplastic Syndromes | 1 | 1997 | 93 | 0.030 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2016 | 44 | 0.030 |
Why?
|
| Gene Deletion | 1 | 2017 | 312 | 0.030 |
Why?
|
| Corpus Striatum | 1 | 1996 | 98 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2018 | 312 | 0.030 |
Why?
|
| Allosteric Regulation | 1 | 2016 | 71 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 4 | 2 | 1993 | 17 | 0.030 |
Why?
|
| Embryo, Mammalian | 1 | 1996 | 158 | 0.030 |
Why?
|
| Genome-Wide Association Study | 1 | 2018 | 361 | 0.030 |
Why?
|
| Molecular Conformation | 1 | 2016 | 115 | 0.030 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2016 | 86 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2016 | 128 | 0.030 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 1 | 2016 | 85 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2016 | 233 | 0.030 |
Why?
|
| Models, Genetic | 1 | 1996 | 266 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2016 | 203 | 0.030 |
Why?
|
| Binding Sites | 1 | 2018 | 921 | 0.030 |
Why?
|
| Drug Discovery | 1 | 2016 | 96 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2016 | 203 | 0.030 |
Why?
|
| Protein Multimerization | 1 | 2016 | 181 | 0.030 |
Why?
|
| Microscopy, Confocal | 1 | 2016 | 240 | 0.030 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2016 | 146 | 0.030 |
Why?
|
| Structure-Activity Relationship | 1 | 2016 | 354 | 0.030 |
Why?
|
| Protein Interaction Maps | 1 | 2015 | 35 | 0.030 |
Why?
|
| Wound Healing | 1 | 2016 | 193 | 0.030 |
Why?
|
| Small Molecule Libraries | 1 | 2015 | 57 | 0.030 |
Why?
|
| Age of Onset | 1 | 1994 | 174 | 0.030 |
Why?
|
| Microscopy, Fluorescence | 1 | 2016 | 401 | 0.030 |
Why?
|
| Repressor Proteins | 1 | 1996 | 351 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2016 | 869 | 0.030 |
Why?
|
| Genetic Markers | 4 | 1995 | 129 | 0.030 |
Why?
|
| Cell Movement | 1 | 2016 | 480 | 0.030 |
Why?
|
| Adolescent | 1 | 2004 | 6306 | 0.030 |
Why?
|
| Genes, Tumor Suppressor | 1 | 1994 | 78 | 0.030 |
Why?
|
| Proteins | 2 | 1996 | 764 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2016 | 1162 | 0.020 |
Why?
|
| Liver | 1 | 1996 | 871 | 0.020 |
Why?
|
| Gene Library | 3 | 1995 | 102 | 0.020 |
Why?
|
| Adult | 2 | 2004 | 17358 | 0.020 |
Why?
|
| Middle Aged | 1 | 2004 | 18273 | 0.020 |
Why?
|
| Gene Expression | 3 | 1996 | 852 | 0.020 |
Why?
|
| Escherichia coli | 1 | 1992 | 714 | 0.020 |
Why?
|
| DNA, Complementary | 2 | 1996 | 165 | 0.010 |
Why?
|
| Chromosomes, Artificial, Yeast | 2 | 1995 | 8 | 0.010 |
Why?
|
| Gene Frequency | 2 | 1994 | 122 | 0.010 |
Why?
|
| Oligodeoxyribonucleotides | 2 | 1994 | 242 | 0.010 |
Why?
|
| Alleles | 2 | 1994 | 453 | 0.010 |
Why?
|
| Biological Evolution | 2 | 1995 | 128 | 0.010 |
Why?
|
| Embryonic and Fetal Development | 1 | 2000 | 46 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 2000 | 300 | 0.010 |
Why?
|
| Smad5 Protein | 1 | 1999 | 7 | 0.010 |
Why?
|
| Yolk Sac | 1 | 1999 | 5 | 0.010 |
Why?
|
| Gene Targeting | 1 | 1999 | 77 | 0.010 |
Why?
|
| Hematopoietic Cell Growth Factors | 1 | 1997 | 4 | 0.010 |
Why?
|
| CCAAT-Enhancer-Binding Proteins | 1 | 1997 | 28 | 0.010 |
Why?
|
| Polycomb Repressive Complex 2 | 1 | 1996 | 17 | 0.010 |
Why?
|
| Recombination, Genetic | 1 | 1997 | 255 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 1996 | 364 | 0.010 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 1999 | 663 | 0.010 |
Why?
|
| Chromosome Walking | 1 | 1995 | 1 | 0.010 |
Why?
|
| Sequence Tagged Sites | 1 | 1995 | 3 | 0.010 |
Why?
|
| DNA, Neoplasm | 1 | 1994 | 61 | 0.010 |
Why?
|
| DNA, Satellite | 1 | 1994 | 24 | 0.010 |
Why?
|
| Conserved Sequence | 1 | 1995 | 173 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 1995 | 161 | 0.010 |
Why?
|
| Exons | 1 | 1995 | 208 | 0.010 |
Why?
|
| Breast | 1 | 1995 | 191 | 0.010 |
Why?
|
| Drosophila | 1 | 1996 | 480 | 0.010 |
Why?
|
| Chromosome Banding | 1 | 1992 | 13 | 0.010 |
Why?
|
| Hybrid Cells | 1 | 1992 | 19 | 0.010 |
Why?
|
| Codon | 1 | 1992 | 58 | 0.010 |
Why?
|
| Placenta | 1 | 1992 | 69 | 0.010 |
Why?
|
| Point Mutation | 1 | 1992 | 168 | 0.010 |
Why?
|
| Chromosomes, Bacterial | 1 | 1992 | 43 | 0.010 |
Why?
|
| Plasmids | 1 | 1992 | 294 | 0.010 |
Why?
|
| DNA, Bacterial | 1 | 1992 | 261 | 0.010 |
Why?
|
| Transduction, Genetic | 1 | 1992 | 243 | 0.000 |
Why?
|
| Pregnancy | 1 | 1992 | 2374 | 0.000 |
Why?
|